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Bladder cancer (BC) is a frequently diagnosed malignancy affecting predomi-
nantly adult and elderly populations. It is expected that due to the longer life time,
BC will become even more frequent in the future; thus in consequence, it will rep-
resent serious health problem of older society part. The treatment of advanced BC
is mostly ineffective due to its very aggressive behavior. So far, no effective
targeted therapy is used for BC treatment. Here, we found that BC is characterized
by lower protein levels of BRM, INI1, and BAF155 main subunits of SWI/SNF
chromatin remodeling complex (CRC) which is involved in global control of gene
expression and influences various important cellular processes like: cell cycle con-
trol, apoptosis, DNA repair, etc. Moreover, the expression of SMARCA2, a BRM
encoding gene, strongly correlated with BC metastasis and expression of such
metabolic genes as PKM2 and PRKAA1. Furthermore, the analysis of T24 and
5637 commonly used BC cell lines revealed different expression levels of meta-
bolic genes including FBP1 gene encoding Frutose-1,6-Bisphosphatase, an enzyme
controlling glycolysis flux and gluconeogenesis. The tested BC cell lines exhibited
various molecular and metabolic alterations as well as differential glucose uptake,
growth rate, and migration potential. We have shown that BRM subunit is
involved in the transcriptional control of genes encoding metabolic enzymes.
Moreover, we found that the FBP1 expression level and the SWI/SNF CRCs may
serve as markers of molecular subtypes of BC. Collectively, this study may provide
a new knowledge about the molecular and metabolic BC subtypes which likely
will be of high importance for the clinic in the future.
Abbreviations: BC, bladder cancer; MIBC, muscle invasive bladder cancer; PKM, pyruvate kinase M; PRKAA1, AMPKα1 encoding gene; SWI/SNF,
ATP-dependent chromatin remodeling complex; TCGA, The Cancer Genome Atlas.
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1 | INTRODUCTION
Bladder cancer (BC) is the one of the most commonly
diagnosed malignant cancers all over the world. This dis-
ease is reported as the 13th cause of death.1 In western
countries, the muscle invasive BC (MIBC) represents
around 25% of all newly diagnosed BC cases. Up to 30%
of non-muscle invasive BC (NMIBC) develops progres-
sion to muscle invasive BC.2 Additionally, in 5–15% of
BC patients the unresectable or metastatic disease is
found at the time of diagnosis.3 Molecularly and clini-
cally, BC is a heterogeneous disease. The large scale
transcriptomic analysis revealed the existence of the
luminal and basal subtypes of MIBC, similarly as it is
reported for breast cancer.4 The basal subtype had much
worse prognosis and survival rate than luminal sub-
type.5,6 So far, no targeted therapy is recommended to
treat advanced and/or metastatic BC and palliative
cystectomy is performed. The prognosis in metastatic BC
is generally extremely poor.7
Mutations in various genes were identified in BC. One
of them is ARID1A truncating mutation8 affecting the pro-
duction of proper BAF250a subunit of SWI/SNF ATP-
dependent chromatin remodeling complex (CRC).9 The
SWI/SNF CRC is composed of several core and non-core
subunits. The core complex of canonical SWI/SNF CRCs
is formed by one ATPase subunit: BRM or BRG1; two
SWI3-type proteins: BAF155 and/or BAF170 and one
SNF5-type INI1 protein.9 Subunits of SWI/SNF CRC were
found to be dysregulated in ccRCC and other malignant
cancers.10–14 Noteworthy, the loss of some SWI/SNF sub-
units was observed in undifferentiated/dedifferentiated
urothelial cancers, mostly BCs.15
In this study we found that BC is characterized by
downregulation of BRM, BAF155, and INI1 the core sub-
units of SWI/SNF CRCs in advanced BC samples derived
from 45 patients. The expression of SMARCA2, a BRM
ATPase encoding gene, strongly correlated with the
expression of PKM2 and PRKAA1 genes, and metastasis,
indicative of the existence of metabolic alterations in
BC. We found that the T24 and 5637 BC cell lines are fea-
tured by differential expression of genes coding for cru-
cial metabolic enzymes, various abilities to glucose
uptake, and different aggressiveness. The differential
characteristics of T24 and 5637 cell lines including the
differential expression of EMT marker genes suggests
that they may represent various BC subtypes. The
observed alterations of various metabolic enzymes
indicate that impaired glycolysis flux and gluconeogene-
sis may be characteristic features of the BC basal subtype.
Subsequently, we have shown that the FBP1 expression
level and the SWI/SNF CRCs may serve as signatures for
molecular subtypes of BC.
2 | EXPERIMENTAL PROCEDURES
2.1 | Ethics statement
This study was performed in accordance with the Decla-
ration of Helsinki and upon approval by the Ethics Com-
mittee in Maria Sklodowska-Curie National Research
Institute of Oncology (MSCNRIO), Warsaw, Poland. All
patients were informed about study and provided written
informed consent, and were informed that their privacy
would be maintained.
2.2 | Study subjects
Biological material was obtained from Maria Sklodowska-
Curie National Research Institute of Oncology in
Warsaw. Forty-five formalin-fixed, paraffin-embedded
samples of patients with BC were analyzed. All sam-
ples were characterized by pathologist for type, stage
(Tumor, Node, Metastasis [TNM] classification) and
tumor grade.
2.3 | Immunohistochemistry staining
and scoring
Immunohistochemistry (IHC) was performed on
3.5-μm sections of paraffin-embedded tissue samples.
These sections were deparaffinized with xylene and
rehydrated with descending ethanol concentrations
(from 96 to 50%). Antigen exposure was obtained by
heat-induced epitope retrieval performed in Target
Retrieval Solution (Dako) for 25 min at 96C. After
cooling, tissues were treated with Peroxidase Blocking
Reagent (Dako) for 5 min, followed by incubation with
appropriate monoclonal antibody (Supplementary Table 1)
and labeled with EnVision FLEX+, Mouse, High pH
Detection System (Dako). The color product occurred as a
result of horseradish peroxidase and 3,30-diaminobenzidine
tetrahydrochloride reaction. Nuclear imaging was visualized
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with hematoxylin staining (DAKO) for 20 s. Histological
score (H-score) was calculated according to the follow-
ing formula:
H−score= 3*percentage of high stained cells
+ 2*percentage of medium stained cells
+ percentage low stained cells
2.4 | Cell culture and transfection
T24 (Human urinary bladder with transitional cell car-
cinoma) and 5637 (Human urinary bladder grade II car-
cinoma) cell lines were obtained from ATCC global
biological resource and standards organization. All
lines were authenticated by ATCC. T24 cells were cul-
tured in DMEM (Biowest) supplemented with 10% FBS
(Biowest) and 5637 cells—in RPMI (Biowest) with 10%
FBS (Biowest). Culture conditions were 37C, 5% CO2,
and 95% humidity. These adherent cell lines were pas-
saged once in 3–4 days by treatment with trypsin
(Biowest). For BRM transient overexpression the
pcDNA6.2 vector and pcDNA6.2 with cloned in frame
full length BRM cDNA (BRMox) were used. The trans-
fection of the BC cell lines was performed using
Lipofectamine 2000 according to the protocol. Transfec-
tion level was evaluated using qRT-PCR with
SMARCA2 specific primers.
2.5 | qRT-PCR
Total RNA was isolated from ~5 × 106 of T24 and 5637
cells using ReliaPrep RNA Miniprep Systems (Promega)
according to manufacturer's protocol. One microgram of
total RNA was transcribed by reverse transcriptase using
Transcriptor First Strand cDNA Synthesis Kit (Roche)
according to the standard protocol. Gene expression was
evaluated using the comparative CT (2−ΔΔCT) method
with SybrGreen (BioRad) and ubiquitin as the reference
gene. Primers' sequences specific for studied genes are
present in Supplementary Table 2.
2.6 | Western blot
Total protein extract was isolated from 3 × 106 of T24 and
5637 cell lines pellets. Thirty micrograms of protein
extract was loaded on each line of 12% SDS-PAGE gel
with 0.5% TCE (BioRad). After separation, the proteins
were visualized on UV light, in order to examine proper
protein loading (stain-free loading control).16
Western blotting using in-gel protein labeling as a nor-
malization control: stain-free technology16 and transferred
(70 V, 2 h, and 4C) on PVDF membrane (Milipore).
Membrane was blocked on 5% milk in TBS with 0.1%
Tween-20 (TBS-T). Incubation with primary antibodies
was performed at 4C, overnight. Antibodies details and
working concentrations are present in Supplementary
Table 3. After incubation with primary antibodies, mem-
branes were washed three times for 5 min in TBS-T and
probed with secondary antibodies (Supplementary
Table 3) for 1 hr at RT. Chemiluminescence signal was
detected by WesternBright Quantum detection kit
(Advansta) using Azure Biosystems chemiluminescence
detection system.
2.7 | Transcriptome database analysis
The microarray datasets obtained from Gene Omnibus
Database (GEO) with accession number GSE31684 from
93 BC samples17,18 were reanalyzed using GeneSpring
GX software (Agilent) according to the advanced
workflow.
2.8 | Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 software by Shapiro–Wilk normality test, paired t-test,
Mann–Whitney rank test for independent samples and
multiple regression. p-value < .05 was considered as sta-
tistically significant. Log-rank test was used to estimate
probability of surviving. The relationship between
SMARCA2 expression and expression of other genes was
estimated using Pearson correlation coefficient.
2.9 | SurvExpress databases
In this study the survival analysis was performed for
SMARCA2 and FBP1 genes on BC data-based deposited
in GEO accession number GSE1350719 using the
SurvExpress bioinformatics tool (http://bioinformatica.
mty.itesm.mx:8080/Biomatec/SurvivaX.jsp).20
2.10 | Ualcan database
Ualcan (http://ualcan.path.uab.edu) is an online avail-
able tool, which uses The Cancer Genome Atlas (TCGA)
RNA-seq and clinical data from various cancer types. In
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this study, Ualcan was used to compare the expression of
SMARCA2, SMARCC1, and SMARCB1 in TCGA BC sam-
ples and for comparative analysis of tumor and normal
tissue.21 The 550 genes positively correlated with
SMARCA2 expression were further used for Gene Ontol-
ogy analysis using GO tools https://go.princeton.edu/.
The GO analysis was performed using GO Term Finder
tool, processes as ontology aspect and H. sapiens as
annotation.
2.11 | Glucose uptake analysis
Glucose uptake by the T24 and 5637 cell lines was mea-
sured using Glucose Uptake-Glo™ Assay (Promega). Five
thousand cells of each line were plated into 96-well plate
(0.32 cm2) and cultured for 24 hr and treated according
to protocol.
2.12 | Immunocytochemistry
Immunocytochemistry assay was performed on 40,000 cells
plated into 4-well plate LabTek® II Chamber Slide (Nunc).
The cells were cross-linked using 4% paraformaldehyde for
20 min and incubated with Triton X-100 (Sigma-Aldrich)
for 5 min. Endogenous signal was blocked using 1% BSA
(Bioshop) solution (in PBS) for 30 min. The following steps,
starting from specific antibody incubation (Supplementary
Table 1), were performed as it was described in Immuno-
histochemistry subsection.
2.13 | Cell growth analysis
Ten thousand cells of T24 and 5637 cell lines were plated
into 24-well plate (1,9 cm2 each well) and cultured in
appropriate conditions. Cells were counted using Neu-
bauer hematocytometer (Sigma-Aldrich) after every 24 hr
for 5 days.
2.14 | Scratch assay—Migration test
Five lakh cells of T24 and 5637 cell lines were plated into
6-well plate (9.5 cm2 each well) and cultured in appropri-
ate conditions for 24 hr, when the confluency of the cells
achieved 100%. Then, the media were changed and sup-
plemented with 60 μM hydroxyurea (Sigma-Aldrich).
Two hundred microliters pipette tips were used to obtain
gaps through the center of well. Width of the gaps was
captured and measured in respective time points: 0, 2,
4, 6, and 24 hr.
3 | RESULTS
3.1 | Characteristics of patients enrolled
in this study
Forty-five patients with diagnosed BC which underwent
the cystectomy in MSCNRIO in Uro-oncology Clinic are
summarized in Table 1.
3.2 | Alterations in SWI/SNF core
subunits abundance characterize
advanced BC
The mutations in ARID1A gene encoding BAF250a sub-
unit of the SWI/SNF CRC were found in BC, although
mutations in genes coding for core subunits were identi-
fied only with low frequency.8,22 The self-regulation and
interdependence between SWI/SNF subunits expression
were already described10; therefore, we examined the
abundance of three main SWI/SNF CRC subunits: BRM
ATPase, BAF155, and INI1 in advanced MIBC compared
with adjacent urothelium using IHC on paraffin-
embedded samples. The BRM protein was found in the
nucleus in both normal and cancer cells (Figure 1a), but
in BC the amount of BRM was significantly lower than in
TABLE 1 Clinico-pathological characteristics of patients




















Abbreviation: TNM, Tumor, Node, Metastasis.
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normal urothelium p-value < .0001 (Figure 1b). The
decrease of BRM abundance was observed in nearly all
examined paired samples. Moreover, the TCGA dataset
analysis revealed significant downregulation of
SMARCA2 (a BRM encoding gene) expression in BC
compared with healthy tissue (Figure 1c). Of note, the
strongest decrease of SMARCA2 expression was observed
in basal/squamous (p-value = 5.7E-10) and luminal pap-
illary (p-value = 4.48E-08) molecular BC subtypes
(Figure 1d). Consistently, the increased methylation of
SMARCA2 promoter region was observed in BC samples
compared with normal tissue and in higher stage of the
disease (Figure 1e,f).
The IHC examination demonstrated additional
strongly decreased abundance of INI1 protein in BC (p-
value = .0005, Figure 2a,b) further indicating the aber-
rations of SWI/SNF CRCs in this type of cancer;
however, in some cases, the INI1 level was not changed
or even increased in cancer cells compared with the
corresponding healthy urothelium. Surprisingly, the
expression of SMARCB1 gene encoding INI1 was
increased in BC compared with healthy tissue
(Figure 2c).
The BC cells were characterized by the significant
decrease of BAF155 protein, p-value < .0001 (Figure 2d,
e); however, similarly as for INI1 protein in some cases,
no differences between normal tissue and cancer were
found. According to TCGA database, the expression
levels of SMARCC1 gene encoding BAF155 protein were
similar in BC cells and healthy tissue (Figure 2f). No cor-
relation between abundance of BRM, INI1, and BAF155
in BC cells was observed (data not shown). Collectively,
our results show the deregulation of various SWI/SNF
CRC classes in BC.
FIGURE 1 Downregulation of BRM, the central ATPase of SWI/SNF chromatin remodeling complex and SMARCA2, a BRM encoding
gene, characterize bladder cancer. The protein level of BRM ATPase is decreased in advanced bladder cancer samples compared with normal
urothelium—the IHC with anti-BRM antibody (magnification 20× and 63×) (a). The statistical analysis of BRM abundance in 45 MIBC
patient samples versus healthy tissue analyzed using H-score method indicates significant BRM downregulation in BC, p-value < .0001 (b).
SMARCA2, a BRM encoding gene, exhibits downregulated expression BC samples versus normal tissue. The bladder cancer TCGA datasets
were analyzed, p-value = 2.60E-06 (c). Different SMARCA2 expression patterns are exhibited by various BC molecular subtypes: neuronal, p-
value = 4.22E-04; basal squamous, p-value = 5.70E-10; luminal, p-value = 1.33E-02, luminal infiltrated, p-value = 1.08E-01; luminal
papillary, p-value = 4.49E-08 (d). High methylation rate of SMARCA2 gene promoter region in BC samples is observed when compared with
healthy urothelium, p-value = 4,92E-11 (e). SMARCA2 methylation status depends on stage of the disease: stage 1, p-value = 1.75E-01; stage
2, p-value = 9.02E-09; stage 3, p-value = 9.53E-09; stage 4, p-value = 1.30–08 (f). The Beta value on the graph indicates level of DNA
methylation 0—unmethylated and 1—fully methylated. BC, bladder cancer; IHC, Immunohistochemistry; TCGA, The Cancer Genome Atlas
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3.3 | Low expression of BRM encoding
gene associates with patient poor survival
We found that BRM protein level is downregulated in the
most of analyzed BC samples, thus we decided to
reanalyze microarray dataset available in Gene Expression
Omnibus database (GEO accession number GSE3168417).
This analysis revealed that the low SMARCA2 gene
expression did not correlate with clinical stage of the dis-
ease (Figure 3a) but we found a strong correlation
between low SMARCA2 transcript level and BC metastasis
p-value < .0001 (Figure 3b). The survival analysis using
log-rank test indicated the lower recurrence free survival
for patients with low expression of SMARCA2 gene
(Figure 3c) p-value = .0217 and the overall survival was
significantly lower for BC patients with low expression of
BRM encoding gene—SMARCA2 (Figure 3d). To confirm
the association of SMARCA2 expression with BC patients'
survival the analysis of large datasets (GSE13507)19 was
performed using SurvExpress. Interestingly, the low
SMARCA2 expression was associated with poor survival of
BC patients (Figure 3e), predominantly for patient with
muscle invasive BC but not for NMIBC (Figure 3f,g).
3.4 | SMARCA2 expression correlates
with PKM isoform 2 (PKM2) and PRKAA1
gene expression in BC tumors
As SWI/SNF CRC is involved in sucrose metabolism in
yeast,23 and in the regulation of nutrient sensing and
metabolism control in mammals,24 we assessed the
potential correlation of SMARCA2 expression with
expression of genes coding for main glucose metabolism
enzymes including: FBP1 (fructose-1,6- bisphospatase),
GAPDH (glyceraldehyde 3-phosphate dehydrogenase),
ENO1 (enolase1), LDHA (lactate dehydrogenase), PKM2
(pyruvate kinase M), ALDOA, ALDOB, ALDOC
(aldolase A, B and C), and IDH1 (isocitrate dehydroge-
nase 1)—a Krebs cycle gene as well as PRKAA1 gene
FIGURE 2 Bladder cancer is featured by downregulation of BAF155 and INI1 core subunits of SWI/SNF chromatin remodeling
complex. Comparison of INI1 expression pattern in healthy urothelium and advanced bladder cancer tissue using IHC method,
magnification 20× and 63× (a). INI1 abundance is decreased in MIBC samples when compared with normal tissue; the analysis was
performed using H-score calculation method, p-value < .0001 (b). The primary BC tumor is characterized by the overexpression of
SMARCB1, the INI1 encoding gene—TCGA BLCA datasets analysis, p-value = 2.21E-05 (c). MIBC is characterized by the statistically
significant lower BAF155 protein level when compared with healthy urothelium; IHC using anti-BAF155 antibody, magnification 20× and
63× (d). The BAF155 subunit of SWI/SNF CRCs is less abundant in BC when compared with normal tissue. The H-score analysis of
45 patients cohort, p-value < .0001 (e). The SMARCC1 gene is expressed at similar level in primary BC tumor and normal tissue. TCGA
BLCA datasets analysis p-value = .0588 (f). BC, bladder cancer; CRC, chromatin remodeling complex; IHC, immunohistochemistry; TCGA,
The Cancer Genome Atlas
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encoding the AMPKα1 subunit of AMP-activated Protein
Kinase (AMPK), the evolutionarily conserved ancient
gauge of metabolism. The statistically significant correla-
tion between expression of SMARCA2 and PKM2 and
PRKAA1 genes were found (Figure 4a). In BC samples
with low SMARCA2 expression, a significantly higher
expression of PKM2 was observed (p-value = .0081) com-
pared with samples with high SMARCA2 expression
(Figure 4b). The exhaustive transcriptomic analysis using
TCGA datasets indicated the strongest PKM2 over-
expression in basal squamous and luminal papillary BC
subtypes (Figure 4c) which exhibited low SMARCA2
expression (Figure 1d). Similarly to PKM2, the PRKAA1
gene expression was elevated in BC samples with low
SMARCA2 expression (p-value = .0378; Figure 4d). Col-
lectively, our results indicated that BRM encoded by
SMARCA2 gene may be a negative regulator of metabolic
processes dependent on PKM2 and AMPK in BC. The
GO classification of genes positively correlating with
SMARCA2 expression revealed the enrichment of various
GO classes related to metabolic processes: like nucleic
acid metabolism, RNA metabolism, cellular metabolic
process, heterocycle metabolic process, nucleobase-
containing compound metabolic process, cellular aro-
matic compound metabolic process and chromosome
organization, chromatin organization, and histone modi-
fications (Supplementary Dataset 1).
3.5 | T24 and 5637 BC cell lines exhibit
different molecular and metabolic
alterations
The T24 and 5637 BC cell lines are commonly used for
the molecular study of BC. To verify the glucose metabo-
lism in these two lines the glucose uptake analysis was
FIGURE 3 The altered expression of SMARCA2 correlates with clinical observations. There is no correlation between low and high
SMARCA2 expression and clinical stage of the disease, p-value = .36 (a). Low SMARCA2 expression correlates with metastasis frequency, p-
value < .0001 (b). Low SMARCA2 expression correlates with worse recurrence free survival, p-value = .0217 (c). Worse overall survival of
the patients, p-value = .0397 (d). Low expression level of SMARCA2 correlates with reduced survival rate for BC patients (e). There is no
correlation between SMARCA2 expression level and overall survival in MIBC patients (f). There is correlation between SMARCA2
expression level and MIBC patients (g). BC, bladder cancer; MIBC, muscle invasive bladder cancer
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performed. Interestingly, the T24 cell line exhibited sta-
tistically significant stronger glucose uptake than 5637
cell line p-value < .0001 (Figure 5a) suggesting the occur-
rence of the faster glycolysis flux in T24 cell line. The
analysis of expression levels of genes encoding main gly-
colysis enzymes, namely: LDHA, ALDOA, ENO1, HK,
GAPDH, and PFK indicated higher expression of LDHA,
ALDOA, HK, and GAPDH in T24 compared with 5637 BC
cell line (Figure 5b). Interestingly, the expression of
AMPKα1 encoding gene was dramatically decreased in
5637 BC cells (Figure 5c). Interestingly, no significant
alterations of PKM2 expression were observed between
tested cell lines on both transcript and protein levels
(Figure 5c,d). The opposite effect for Fructose-1,-
6-Bisphosphatase (FBP1) enzyme abundance was
observed. In T24 line, FBP1 protein level was decreased
compared with 5637 cell line (Figure 5e) and consistently
the FBP1 transcript level was more than 60-fold higher in
5637 BC cells in comparison with T24 cell line
(Figure 5e). Moreover, obtained data strongly suggest that
these two BC cell lines implement various metabolic pro-
grams. T24 and 5637 BC cells also differ phenotypically;
the T24 cells are bigger and more spindle-shaped com-
pared with more compacted 5637 cells (Supplementary
Figure 1). The spindle shape resembles more mesenchy-
mal/basal phenotype; therefore, the expression analysis
of epithelial to mesenchymal markers (CDH1, CDH2,
SNAIL, and VIM) was performed. As we suspected, in
T24 cell lines the level of vimentin and Snail was higher
than in 5637 cells (Figure 5f). Interestingly, although the
CDH2, an N-cadherin encoding gene, was ~2.5-fold
upregulated in 5637 cell line the level of E-cadherin
encoding gene CDH1 (the epithelial marker) was more
than 400 times higher in 5637 cells (Figure 5f). These
results strongly suggest that T24 cell line is more basal
than 5637 BC cell line which seems to be more luminal.
Additionally, the T24 cell line exhibits statistically signifi-
cant higher growth rate (Figure 5g) and the T24 cells
migrate more collectively than 5637 cells which migrate
rather as single cells (Supplementary Figure 2).
3.6 | T24 and 5637 BC cell lines exhibit
differential expression of SWI/SNF CRCs
subunits
The SWI/SNF controls the expression of E-cadherin25,26
and is involved in glucose metabolism control; therefore,
FIGURE 4 Metabolic alterations characteristic for bladder cancer correlate with patient outcome. Significant correlation of SMARCA2
gene expression with expression of PKM2 and PRKAA1, genes involved in glucose metabolism, is observed (d). Low SMARCA2 expression
associates with high transcript level of PKM2 gene, p-value < .001 (e). There is a strong association of PKM2 transcript level with molecular
stage of bladder cancer: neuronal, p-value = 1.99E-02; basal squamous, p-value = 1.62E-12; luminal, p-value = 7.71E-01, luminal infiltrated,
p-value = 3.76E-04; luminal papillary, p-value = 2.58E-08 (f). Low SMARCA2 expression associates with higher PRKAA1 gene expression (g)
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we evaluated the alterations of SWI/SNF subunits expres-
sion in T24 and 5637 BC cell lines. Slight differences
between BRM level in T24 and 5637 BC cell lines were
detected (Figure 6a). More pronounced expression
changes were observed for BAF155 and BRG1 subunits of
SWI/SNF CRCs as both proteins were overexpressed in
5637 line compared with T24 cells (Figure 6b,c). The level
of INI1, in both lines was comparable (Figure 6d). The
specificity of used antibody against BAF155 and BRM
was validated on breast cancer cell line with amiRNA
targeting SMARCC1 or SMARCA2 (Supplementary
Figure 4). The INI1 antibody used in both IHC and WB
analysis was validated in Sarnowska et al.10 The evalua-
tion of transcript level indicated that SMARCA4 (BRG1)
and SMARCC1 (BAF155) consistently exhibited elevated
expression in 5637 cell line, while the expression level of
SMARCA2 (BRM) was comparable in both cell lines
(Figure 6e). PKM and PRKAA1 expression correlates with
SMARCA2; SWI/SNF subunits encoding genes are regu-
lated by themselves10; and SWI/SNF CRCs are involved
in control of glucose metabolism genes; therefore, we
investigated the influence of BRM overexpression on the
expression on glycolysis enzymes encoding genes,
SWI/SNF subunits and PRKAA1. The transient over-
expression of BRM was performed in both T24 and 5637
cell lines, respectively (Supplementary Figure 5). Interest-
ingly, the BRM overexpression caused elevated expres-
sion of almost all examined glycolysis genes including
PKM2 except FBP1 in T24 BC cell lines, but not in 5637
cells, where FBP1 increased after BRM overexpression.
By contrast, the PRKAA1 transcript was downregulated
in both T24 and 5637 cell lines (Figure 6f,g). Similarly, in
FIGURE 5 T24 and 5637 bladder cancer cell lines exhibit different glucose metabolisms, EMT markers statuses, and growth rates. The
5637 BC cell line exhibits lower glucose uptake rate compared with T24 cells (a). The expression of glycolysis enzymes encoding genes and
PRKAA1 is significantly lower in 5637 cell line than in T24 (b, c). The PKM2 protein level is slightly higher in T24 bladder cancer cell line
than in 5637 line (d). The expression of FBP1 in T24 BC line is lower on both protein and transcript level compared with 5637 cell line (e).
The EMT markers VIM and SNAIL are overexpressed in T24 cells but CDH1, an E-cadherin encoding gene, is dramatically elevated in 5637
cell line (f). T24 cells grow significantly faster than 5637 cells (g). BC, bladder cancer
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T24 line BRM induced the higher expression of all exam-
ined SWI/SNF encoding genes, but in 5637 only
SMARCC1/BAF155 and SMARCC2/BAF170 increased
while SMARCA4 and SMARCB1 expression levels
remained unaltered (Figure 6f,g). This observation
suggested the different roles of BRM and BRM containing
SWI/SNF CRC in these two lines.
3.7 | Low expression of FBP1 gene is
related to patient poor outcome
To assess the impact of FBP1 expression on BC patients'
survival the analysis of GEO database accession number
GSE13507 was performed using SurvExpress approach.
The low expression of FBP1 strongly correlated with poor
survival of BC patients (Figure 7a). Interestingly, the poor
survival was independent on muscle invasion. The TCGA
datasets analysis indicated no differences in FBP1 expres-
sion in BC cells compared with healthy tissue
(Figure 7b), although the strong downregulation was
observed in neuronal (p-value = 8.14E-03) and basal
squamous (p-value = 9.49E-03) BC subtypes (Figure 7c).
Moreover, the analysis of GSE31684 datasets indicated
that the low FBP1 expression level correlates with clinical
stage of the disease (Figure 7d), more frequent urothelial
recurrence (Figure 7e) and metastasis (Figure 7f). Thus,
the FBP1 expression may serve as a prognostic marker
for BC patients.
4 | DISCUSSION
In 2014, 262 MIBC samples were analyzed, and the two
main basal and luminal BC subtypes were identified as
a result of this study. These molecular subtypes resem-
bled the breast cancer, where such subtypes are also
defined.6 More deep analysis revealed that BC may be
divided to more molecular subtypes. Currently, based
on TCGA data from 2017 in MIBC five subtypes were
identified, namely luminal-papillary, luminal-infil-
trated, luminal, basal squamous, and neuronal.27 In
basal subtypes of breast cancer—triple negative breast
cancer,28,29 the growth and proliferation depend on the
FIGURE 6 Bladder cancer cell lines exhibit various molecular characteristics. BRM subunit is overexpressed in T24 line compared with
5637 BC cell line (a), BAF155 (b), and BRG-1 proteins are overaccumulated in 5637 line compared with T24 BC cell line (c). The INI1
protein levels in T24 and 5637 cell lines are similar (d); stain-free method was used as a loading control in (a), (b), (c), and (d). The genes
encoding BRG1 (SMARCA2) and BAF155 (SMARCC1) subunits of SWI/SNF are expressed differentially in T24 and 5637 cell lines (e). BRM
overexpression affects the expression of glucose metabolism genes, PRKAA1 and SWI/SNF subunits in T24 cell line (f). The overexpression
of BRM causes decreased expression of PRKAA1 gene and elevated level of FBP1, SMARCC1, and SMARCC2 genes in 5637 cell line (g). BC,
bladder cancer
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BRM and BRG1 central ATPases of the SWI/SNF CRCs,
which is involved in the control of numerous regulatory
processes.30 In samples of advanced MIBC the strong
decrease of BRM protein level corresponding to down-
regulation of SMARCA2 gene expression was detected.
Further analysis indicated that the impairment of
SWI/SNF CRCs in BC is not restricted to the BRM
ATPase subunit only, as INI1 and BAF155, another
SWI/SNF core subunits were less abundant in cancer
cells. However, SMARCB1 gene encoding INI1 protein
was strongly upregulated suggesting affected regulation
at the posttranscriptional and/or protein level in
BC. Although, in some particular cases the levels of
SWI/SNF subunits were intact in cancer cells compared
with healthy urothelium strongly suggesting the BC
heterogeneity in terms of SWI/SNF complex
abundance.
The SMARCA2 expression was consistently down-
regulated in BC and its expression strongly correlated with
metastasis. The patients with low SMARCA2 expression
exhibited two times more frequent metastasis rate than
patients with high SMARCA2 transcript level. Additionally,
patients with low SMARCA2 expression had lower recur-
rence free survival and overall survival. Interestingly, this
observation was confirmed only for MIBC, what strongly
indicated that the impairment of BRM and SWI/SNF com-
plex may be characteristic for higher aggressive BC.
SWI/SNF complex is known as sucrose metabolism
regulator in yeast. In human cells, SWI/SNF CRCs con-
trol lipid metabolism,31 nutrient metabolism, and signal-
ing.24 Therefore, we assessed the association of
SMARCA2 expression with the main glucose metabolism
genes. Surprisingly, the SMARCA2 correlated with PKM2
gene expression, which encodes a pyruvate kinase M and
expression of PRKAA1 gene coding for the AMPKα1 sub-
unit of AMPK, which controls metabolic homeostasis in
the cells.32 Inactivation of AMPK leads to metabolic
imbalance in the cell and promotes metabolic repro-
gramming. In BC, the low expression of SMARCA2 corre-
lates with higher PRKAA1 and PKM2 expression
indicative of its important role in the control of metabolic
processes in this cancer type. The increased PKM2 level
was observed in BC cell resistant to cisplatin.33 Addition-
ally, the TCGA BLCA database analysis indicated the
SMARCA2 correlation with expression of genes involved
in chromatin organization, transcription and various
metabolic processes including nucleic acid metabolic pro-
cesses, RNA metabolism, cellular metabolic processes,
etc. (Supplementary Dataset 1). Thus, given the observed
alteration in the control of metabolism, our study opens a
new attractive, so far unexplored path which may lead to
better characterization of this disease.
Interestingly, during our study we found that the BC
T24 and 5637 cell lines exhibit differential alterations in
FIGURE 7 Impairment of FBP1 affects the BC patients' outcome. FBP1 expression is associated with BC patients' survival (a). FBP1
gene is expressed at similar levels in primary BC tumor and healthy tissue, p-value = .197724 (b). FBP1 is expressed differentially in various
BC molecular subtypes: neuronal, p-value = 8.14E-03; basal squamous, p-value = 9.49E-03; luminal, p-value = 9.81E-01, luminal infiltrated,
p-value = 1.86E-01, and luminal papillary, p-value = 8.19E-01 (c). FBP1 gene expression is significantly associated with clinical stage of the
disease, p-value = .0312 (d), urothelial recurrence p-value = .0047 (e), and metastasis, p-value = .030 (f). BC, bladder cancer
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the SWI/SNF subunit abundance as well as in the degree
of metabolism-related deregulations including glucose
uptake and expression of glycolysis enzymes encoding
genes. Further, in T24 BC cell line the vimentin and
Snail, the EMT markers were upregulated, as well as E-
cadherin, supporting the hypothesis that T24 and 5637
cell lines represent two different molecular subtypes of
BC. T24 is more basal-like but 5637 is more luminal BC
cell line. The T24 cell line exhibits higher growth rate
what is characteristic for more aggressive basal subtype
of BC. This finding, together with the observation that
the different BC molecular subtypes are featured by vari-
ous extents of SWI/SNF impairment as well as expression
levels of metabolic enzymes, lead us to the conclusion
that the alterations of SWI/SNF complex may be a signa-
ture for these cancer subtypes. Molecularly, BC subtypes
resemble the breast cancer and both basal-like breast
cancer34 and basal squamous BC exhibits dramatic down-
regulation of FBP1 gene which controls glycolysis flux
and gluconeogenesis. In breast cancer, low or absent
expression of FBP1 gene was associated with reduced
Disease-Free Survival.35 Consistently, we observed the
correlation of downregulation of FBP1 expression with
reduced overall survival. The loss of FBP1 in basal-like
breast cancer cells causes increased glucose uptake and
macromolecule biosynthesis, increased PKM2 activity,
maintenance of ATP production under hypoxic condition
and is an essential oncogenic event in epithelial to mes-
enchymal transition of cancer cells.34 In T24 BC cell line,
the low expression of FBP1 was observed and higher glu-
cose uptake compared with 5637 cell line, further indicat-
ing that T24 BC cell line resembles basal-like BC subtype.
Here we provided the first evidences that the impair-
ment of chromatin remodeling machinery, the SWI/SNF
complex, which precisely controls gene expression has a
great importance in the development, progression and
molecular characteristics of BC subtypes. Given the
observed differences between molecular subtypes and
MIBC versus NMIBC we propose the SWI/SNF BRM sub-
unit as a biomarker for some BC types. Our results indi-
cate that the current study of BC biology should be
directed toward the better molecular characteristics of
metabolic and transcriptomic events in this cancer type
which may lead to the identification of a solid basis for
development of new BC treatment strategies.
5 | CONCLUSIONS
Summarizing, significant downregulation of SWI/SNF core
BRM, INI1, and BAF155 subunits was found in MIBC.
Low expression of SMARCA2, a BRM encoding gene, asso-
ciates with metastasis, reduced survival for MIBC patients
and correlates with PKM2 and PRKAA1 genes expression.
Moreover, low FBP1 expression is associated with poor sur-
vival for patients, local recurrence, and metastasis.
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